Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of furosemide syrup in China. Welcome to wholesale bulk high quality furosemide syrup for sale here from our factory. Good service and reasonable price are available.
Furosemide syrup is an oral solution formulation mainly composed of furosemide (furomex). Its chemical name is 2- [(2-furanmethyl) amino] -5- (sulfamoyl) -4-chlorobenzoic acid, and its molecular formula is C₁₂H₁₁ClN₂O₅S, with a molecular weight of 330.75. This drug belongs to Loop Diuretics, which exerts a potent diuretic effect by inhibiting the reabsorption of sodium and chloride ions by the thick segment of the ascending branch of the renal tubular medullary loop, while also having a vasodilatory effect.
It inhibits the active reabsorption of Na ⁺ and Cl ⁻ by the thick segment of the ascending branch of the renal tubular medullary loop, reduces the osmotic pressure of the renal medullary interstitium, lowers the renal tubular concentration function, and thus increases the excretion of electrolytes such as water, sodium, chloride, potassium, calcium, and magnesium.Compared to tablets, syrup formulations can reduce gastrointestinal irritation and improve patient compliance.
our products form
Furosemide COA
Applications in Cardiovascular System Diseases
Treatment of Acute Pulmonary Edema
Furosemide syrup is a core diuretic for clinical emergency management of acute pulmonary edema. As a potent loop diuretic, it specifically acts on the thick ascending limb of the renal loop of Henle, inhibits the sodium-potassium-chloride cotransporter, blocks the electrolyte reabsorption pathway, and rapidly produces robust diuresis. It constitutes a critical agent for alleviating life-threatening symptoms of acute pulmonary edema.
Acute pulmonary edema is mostly triggered by acute left cardiac failure.
Patients suffer from sharply elevated pulmonary circulation pressure, massive fluid accumulation in alveoli and pulmonary interstitium, presenting critical manifestations including dyspnea, orthopnea, and pink frothy sputum.
Without timely intervention, respiratory and circulatory failure may develop rapidly. The product features rapid oral absorption and fast onset. After administration, urine output rises drastically within a short period to eliminate excess body fluid, markedly reduce systemic blood volume, lower cardiac preload, decrease pulmonary perfusion pressure, and quickly resolve pulmonary interstitial and alveolar edema. Meanwhile, the drug dilates pulmonary venous vessels, reduces pulmonary blood flow, further relieves pulmonary congestion, and improves ventilation and hypoxemia.
Compared with injectable formulations, the syrup offers convenient administration and high patient compliance. It is suitable for patients with relatively stable conditions who can receive oral therapy for acute pulmonary edema, and can also be applied for maintenance treatment after acute symptom relief to consolidate therapeutic efficacy and prevent recurrence. Clinicians must strictly control dosage, adjust administration according to body weight and disease severity, and monitor urine volume, blood pressure (BP) and electrolyte levels to avoid adverse reactions such as hypotension and electrolyte disturbance induced by excessive diuresis.
Chronic cardiac failure (Reduction of Volume Overload)
The core pathological change in patients with chronic cardiac failure is impaired cardiac pumping function accompanied by fluid retention and excessive volume overload, which further leads to limb edema, pulmonary congestion, chest tightness, fatigue and other symptoms. Reducing cardiac volume overload represents one of the core principles for long-term management of this disease.
With potent and efficient hydragogic activity, the product serves as a commonly used oral agent to ameliorate volume overload in chronic cardiac failure, indicated for long-term maintenance therapy in stable-phase chronic cardiac failure patients with mild to moderate fluid retention.
By continuously facilitating excretion of surplus sodium and water, the drug decreases circulating blood volume, lowers end-diastolic ventricular pressure, effectively reduces cardiac preload, cuts myocardial oxygen consumption, improves cardiac pumping efficiency, relieves pulmonary and systemic congestion in chronic cardiac failure patients, and significantly enhances exercise tolerance and quality of life.
Compared with thiazide diuretics, furosemide syrup delivers stronger and faster diuresis and retains satisfactory hydragogic activity even with mild renal impairment, making it appropriate for chronic cardiac failure patients complicated by renal dysfunction.In clinical practice, low-dose long-term maintenance administration is widely adopted. The drug can be used alone or combined with foundational cardiac failure therapies including aldosterone receptor antagonists and β-blockers to achieve synergistic therapeutic effects.
During treatment, regular monitoring of electrolytes, renal function and body weight is required. Dosage shall be dynamically adjusted based on fluid retention status to prevent hypokalemia, hyponatremia and renal injury caused by prolonged diuresis, as well as hypotension and insufficient organ perfusion resulting from excessively low volume load.
Adjunctive Therapy for Resistant Hypertension
Clinically, the product is rarely used as first-line monotherapy for hypertension and is only applied as adjunct hypotensive treatment for resistant hypertension.
Resistant hypertension refers to hypertension that fails to reach target BP despite adequate standard treatment with three or more antihypertensive agents of distinct mechanisms (including diuretics). Most such patients have latent fluid retention and impaired sodium excretion, which act as key contributors to uncontrolled BP.
Through potent natriuresis and diuresis, the product reduces sodium and water accumulation, lowers blood volume and peripheral vascular resistance to assist BP reduction and compensate for limitations of conventional antihypertensive drugs. It demonstrates prominent efficacy for resistant hypertension patients complicated with cardiac failure, edema or renal insufficiency, effectively breaking the pathological cycle of intractable blood BP elevation.
Owing to its strong and sustained hydragogic action, long-term monotherapy easily causes electrolyte disorders and excessive BP fluctuation. Therefore, combination therapy must be strictly followed in clinical practice. It shall be administered at low doses in combination with calcium channel blockers, angiotensin-converting enzyme inhibitors and other antihypertensive agents with carefully controlled treatment duration. During medication, close monitoring of 24-hour urine volume, dynamic BP and electrolyte indicators is required, and treatment regimens shall be adjusted timely to guarantee hypotensive outcomes while minimizing medication risks.
Treatment of Various Edematous Disorders
Edema Secondary to Nephrotic Syndrome
Massive proteinuria in nephrotic syndrome patients leads to sharp decline in plasma albumin and reduced plasma colloid osmotic pressure, causing extensive extravasation of intravascular fluid into interstitial tissue. Coupled with disturbed renal water and sodium excretion, systemic severe pitting edema develops, which may be accompanied by pleural and peritoneal effusion in severe cases. Furosemide syrup ranks among the preferred oral diuretics for edema associated with nephrotic syndrome and rapidly alleviates fluid retention.
Its potent hydragogic effect promotes renal excretion of excess water and sodium, quickly mitigates systemic tissue edema, relieves swelling of eyelids, extremities and trunk, and improves physical discomfort. Given impaired renal filtration function and suboptimal response to conventional diuretics in nephrotic syndrome patients, furomex can still exert powerful diuresis by targeting the thick ascending limb of the loop of Henle, overcoming restrictions from renal filtration disorders. In clinical application, dosage may be appropriately increased for severe edema, followed by gradual tapering for maintenance after symptom improvement.
Attention should be paid to inherent protein loss in nephrotic syndrome patients; prolonged diuresis may aggravate electrolyte disturbance and hypoalbuminemia. Hence, simultaneous monitoring of plasma albumin, electrolytes and renal function is required during treatment. Albumin supplementation can be administered when necessary to elevate plasma colloid osmotic pressure, strengthen edema relief and avoid adverse drug reactions.
Cirrhotic Ascites and Edema
In decompensated liver cirrhosis patients, decreased hepatic synthetic capacity, portal hypertension and activation of the renin-angiotensin-aldosterone system trigger water-sodium retention, peritoneal effusion and lower limb edema.
Recurrent ascites constitutes a typical complication of cirrhosis and severely impairs patients' quality of life.
The product is an essential diuretic in standardized management of cirrhotic ascites. It is frequently combined with spironolactone to achieve synergistic diuresis with potassium retention and sodium excretion, effectively eliminating ascites and limb edema. The drug accelerates excretion of excess sodium and water, reduces intraperitoneal fluid accumulation, lowers portal venous pressure, and relieves abdominal distension, chest tightness and lower limb swelling.
Compared with intravenous preparations, the syrup formulation is better suited for long-term home maintenance treatment of cirrhotic ascites with convenient administration and favorable tolerability.
Patients with liver cirrhosis commonly have varying degrees of hepatic and renal damage and weakened electrolyte regulation capacity. Monotherapy with furomex easily induces severe complications including hypokalemia, hepatic encephalopathy and progressive renal deterioration.
Accordingly, large-dose monotherapy is strictly prohibited clinically, and the principles of combined medication and gradual low-dose escalation must be observed. During treatment, regular monitoring of abdominal circumference, body weight, electrolytes, hepatic and renal function is carried out. Dosage is dynamically adjusted according to ascites regression to balance hydragogic efficacy and medication safety, preventing insufficient effective circulating volume and hepatorenal perfusion injury due to over-diuresis.
The chemical name of furomex is 4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid. Its synthesis takes 2-amino-4-chloro-5-sulfamoylbenzoic acid as the starting material. A furfuryl functional group is introduced via nucleophilic substitution reaction, and high-purity furomex active pharmaceutical ingredient (API) is obtained after refining. The API is further mixed with excipients, dissolved, filtered and sterilized to produce the product.
In the synthesis procedure, the starting material is first dissolved in an alkaline aqueous solution, with pH adjusted to weak alkalinity to create favorable conditions for nucleophilic substitution of amino groups. Subsequently, 2-(chloromethyl)furan reagent is slowly added dropwise. The reaction temperature is controlled at 40–50 °C under constant-temperature stirring for 3–4 hours, enabling nucleophilic substitution between free amino groups of the raw material and 2-(chloromethyl)furan to accurately generate furomex intermediate.
After reaction completion, the reaction solution is acidified with dilute hydrochloric acid to precipitate crude solid. Residual impurities and salts are removed via centrifugal filtration and water washing. Subsequent recrystallization and purification using aqueous ethanol eliminate byproducts and unreacted starting materials to yield high-purity furomex API.
Finally, the refined API is blended with syrup excipients including sucrose, potassium sorbate and purified water, followed by heating, stirring and dissolution, pH adjustment, sterile filtration and filling to obtain the syrup with stable properties and acceptable taste.
This synthetic process features mild reaction conditions, few side reactions and high finished product purity, suitable for industrial production. Meanwhile, it maximally preserves pharmaceutical activity and guarantees clinical efficacy.
Frequently Asked Questions
Why is sodium benzoate often added as a preservative in syrup formulations, but this may have subtle interactions with furomex?
+
-
Both sodium benzoate and furomex are excreted in the body after binding with glycine. In theory, the two may compete for limited glycine resources, especially in infants and young children with liver and kidney dysfunction, which may slightly affect the metabolism and clearance of either drug, but the clinical significance is usually not significant.
What potential impact does the high osmotic pressure environment of syrup have on the stability of the drug itself?
+
-
The high osmotic pressure environment created by high concentration syrup may accelerate the migration of water molecules into the syrup. If the packaging is not tightly sealed, it may cause changes in local water activity, which theoretically may promote the hydrolysis or physical properties of furomexe (such as crystallization), affecting the uniformity of the content.
Hot Tags: furosemide syrup, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale